Bioanalysis with a deeper understanding of biomarkers
With more than 35 years of experience in immunoassay development and a deep understanding of cardiometabolic biology, Mercodia supports pharma and biotech companies with bioanalytical services throughout drug development.
From PK and PD to biomarker analysis and immunogenicity testing, we combine analytical expertise with biological insight to deliver reliable data for critical development decisions.
Bioanalytical services for your development programme
Your molecule, study and development phase determine the right bioanalytical approach. We work with you to develop and deliver fit-for-purpose solutions across preclinical and clinical development.
Pharmacokinetics (PK)
We support the measurement and characterization of drug exposure to inform dose selection, pharmacokinetic profiling and clinical development decisions.
Biomarker analysis
We provide biomarker analysis to help bridge preclinical findings and clinical outcomes, supporting translational decision-making throughout development.
Pharmacodynamics (PD)
We assess pharmacological effects and target engagement to support dose selection, exposure-response evaluation and development decisions.
Immunogenicity testing
Our multi-tiered ADA testing includes screening, confirmatory and neutralizing antibody assays to assess immunogenic risk and potential impacts on exposure, safety and clinical response.
Scientific expertise that supports better decisions
Bioanalytical data is only as valuable as the science behind it. Our scientific expertise spans immunoassays, biomarkers, pharmacology and bioanalytical method development, allowing us to approach complex bioanalytical challenges with both analytical and biological understanding.
We apply this expertise across preclinical and clinical development to develop robust analytical strategies and generate data that is fit for decision-making.
Cardiometabolic expertise that goes beyond bioanalysis
Our deep understanding of cardiometabolic biology is built on more than 35 years of developing immunoassays and supporting research in diabetes, obesity and related diseases.
We combine scientific expertise in biomarkers, immunoassays, pharmacology and bioanalytical method development to understand not only what the data tells us, but what it means in the context of your development programme.
From early preclinical research to clinical development, our cardiometabolic expertise helps us design relevant analytical strategies and generate data that supports better development decisions.
We understand the biology behind the data.
We develop assays, not just run them
Our heritage as an immunoassay developer and manufacturer gives us a unique understanding of assay performance, biomarker biology and analytical risk.
We know what it takes to design robust assays, optimise performance and translate them into reliable bioanalytical methods for regulated studies.
This development expertise allows us to identify potential analytical challenges early and build solutions around the specific requirements of your programme.
Better assays. Lower analytical risk.
A partner, not just a provider
Bioanalysis is an integral part of your development programme. That is why we work as an extension of your team, rather than simply executing a predefined scope.
From initial discussions and study planning through method development, execution and final reporting, we collaborate closely to keep your bioanalytical strategy aligned with your development goals.
A dedicated project manager provides continuity throughout the programme and a clear point of contact from start to finish.
One partner. From planning to final data.
De-risk your bioanalytical studies
Critical development decisions depend on reliable data. Poor assay performance, analytical uncertainty or an unsuitable bioanalytical strategy can introduce unnecessary risk and slow your programme.
Our goal is to help you reduce that risk by combining robust analytical methods, scientific expertise and close collaboration.
Whether you need support with a specific assay or a broader bioanalytical strategy, we help identify the right approach for your molecule, study and development phase.
-
80+
Countries
-
35+
Yearsยดexperience
-
500+
Biomarkers
Go beyond generic bioanalysis
Your programme is unique. Your bioanalytical strategy should be too.
Talk to our bioanalytical experts about your next study.